drugset / Trial / NCT02453386
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).
Timeline
- Start
- 2015-07
- Primary completion
- 2018-01-12
- Completion
- 2018-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tozadenant | Small molecule | 60 mg | Oral |
| Subject | Tozadenant | Small molecule | 120 mg | Oral |